A61K 31/7076 (20130101)
This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Cheng, Jin Q. and Sebti, Said M., "Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof" (2016). USF Patents. 835.
University of South Florida